[1] Bispo JAB, Pinheiro PS, Kobetz EK.Epidemiology and etiology of leukemia and lymphoma[J]. Cold Spring Harb Perspect Med, 2020, 10(6): a034819.
[2] Park H, Youk J, Shin DY, et al. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy[J]. BMC Cancer, 2019, 19(1): 358.
[3] Najafi M, Farhood B, Mortezaee K. Contribution of regulatory T cells to cancer:a review[J]. J Cell Physiol, 2019, 234(6): 7983-7993.
[4] 张启科, 李青芬, 张浩军, 等. 急性白血病并发感染的研究进展[J]. 中华医院感染学杂志, 2019, 29(11): 1756-1760.
[5] 于意. 肿瘤化疗药物应用中不良反应的临床研究[J]. 中国医药指南, 2018, 16(10): 72-73.
[6] 贾莉, 姚志明, 王华, 等. 老年急性白血病的化疗期间院内感染特征及其因素分析[J]. 中华保健医学杂志, 2021, 23(6): 659-660.
[7] Smit J, Kaasch AJ, Søgaard M, et al. Use of glucocorticoids and risk of community-acquired staphylococcus aureus bacteremia: a population-based case-control study[J]. Mayo Clin Proc, 2016, 91(7): 873-880.
[8] Logan C, Koura D, Taplitz R. Updates in infection risk and management in acute leukemia[J]. Hematology Am Soc Hematol Educ Program, 2020, 2020(1): 135-139.
[9] 赵静滨, 崔洪岩, 何健. 外周血Th17/Treg细胞联合超声弹性成像对宫颈病变的临床诊断价值[J]. 临床和实验医学杂志, 2019, 18(6): 652-655
[10] Wang J, Gong R, Zhao C, et al. Human FOXP3 and tumour microenvironment[J]. Immunology. 2023, 168(2): 248-255.
[11] Wang L, Simons DL, Lug XY, et al. Connecting blood and intratumoral T-reg cell activity in predicting future relapse in breast cancer[J]. Nat Immunol, 2019, 20: 1220–30.
[12] Pereira MVA, Galvani RG, Gonçalves-Silva T, et al. Tissue adaptation of CD4 T lymphocytes in homeostasis and cancer[J]. Front Immunol, 2024, 15: 1379376.
[13] Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression implications for anticancer therapy[J]. Nat Rev Clin Oncol, 2019, 16(6): 356-371.
[14] Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells[J]. Immunol Cell Biol, 2018, 96(1): 21-33.
[15] Wegrzyn AS, Kedzierska AE, Obojski A. Identification and classification of distinct surface markers of T regulatory cells[J]. Front Immunol, 2023, 13: 1055805.
[16] Saleh R, Elkord E. Acquired resistance to cancer immunotherapy:role of tumor mediated immunosuppression[J]. Semin Cancer Biol, 2020, 65: 13-27.
[17] Dong Y, Han Y, Huang Y, et al. PD-L1 is expressed and promotes the expansion of regulatory T cells in acute myeloid leukemia[J]. Front Immunol, 2020, 11: 1710.
[18] Liu KS, Fan XQ, Zhang L, et al. Effects of recombinant human interleukin-10 on Treg cells, IL-10 and TGF-β in transplantation of rabbit skin[J]. Mol Med Rep, 2014, 9(2): 639-644.
[19] Xiang M, Guo L, Ma Y, et al. Expression of Th17 and CD4+ CD25+ T regulatory cells in peripheral blood of acute leukemia patients and their prognostic significance[J]. Pak J Pharm Sci, 2017, 30[2(Suppl.)]: 619-624.
[20] Riether C. Regulation of hematopoietic and leukemia stem cells by regulatory T cells[J]. Front Immunol, 2022, 13: 1049301.
[21] 成娟, 马海珍, 张豪. 急性白血病患者T、B淋巴细胞的检测与分析[J]. 中国实验血液学杂志, 2019, 27(2): 327-330.
[22] Krętowska-Grunwald A, Sawicka-ukowska M, Kowalska M, et al. Significance of Th17 and Treg in treatment efficacy and outcome in pediatric acute lymphoblastic leukemia[J]. Int J Mol Sci, 2023, 24(15): 12323.
[23] 杨培仙, 王盼, 方磊, 等. 初诊急性髓系白血病患者外周血中Tregs和IL-35表达的研究[J].中国实验血液学杂志, 2022, 30(6): 1688-1692.
[24] Nakao M, Sugaya M, Fujita H, et al. TLR2 deficiency exacerbates imiquimod-induced psoriasis-like skin inflammation through decrease in regulatory T Cells and impaired IL-10 production[J]. Int J Mol Sci, 2020, 21(22): 8560.
[25] 张志霞, 余丽梅. 肠道菌群对溃疡性结肠炎患者Th17/Treg平衡的调节作用[J]. 山东医药, 2024, 64(19): 108-111.
[26] Wang Z, Liu T, Li Y, et al. Increased Th17 and Treg levels in peripheral bloodpositively correlate with minimal residual disease in acute myeloid leukaemia[J]. Hematology, 2024, 29 (1): 2346 971.
[27] Moniuszko M, Grubczak K, Kowal K, et al. Development of asthmatic response upon bronchial allergen challenge is associated with dynamic changes of interleukin-10-producing and interleukin 10 responding CD4+ T cells[J]. Inflammation, 2014, 37(6): 1945-1956.
[28] Qu G, Chen J, Li Y, et al. Current status and perspectives of regulatory T cell-based therapy[J]. J Genet Genomics, 2022, 49(7): 599-611.
[29] 冀寿健, 徐建明. 免疫检查点抑制剂相关不良反应的研究进展[J]. 中国肿瘤临床与康复, 2018, 25 (7): 894-896.
